-
公开(公告)号：US07754482B2
公开(公告)日：2010-07-13
申请号：US11137807
申请日：2005-05-25
IPC分类号： C12N5/00
CPC分类号： A61K39/39 , A61K39/12 , A61K39/21 , A61K47/642 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , A61K2039/55522 , A61K2039/55527 , A61K2039/55533 , C12N5/0634 , C12N5/0635 , C12N5/0636 , C12N5/0694 , C12N15/86 , C12N2501/23 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00 , C12N2740/15043 , G01N33/505 , G01N33/56972
摘要： The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
摘要翻译： 本发明涉及新型人造抗原呈递细胞（aAPCs）。 aAPC包含至少一种刺激性配体和至少一种共刺激配体，其中配体各自特异性结合感兴趣的T细胞上的同源分子，从而介导T细胞的扩增。 本发明的aAPC可进一步包含可用于扩增感兴趣的T细胞的其它分子。 本发明的aAPC可以用作可以容易地设计用于扩大感兴趣的T细胞的“现成”APC。 此外，可以使用本发明的aAPC来鉴定刺激性，共刺激性和介导感兴趣的T细胞的生长和扩增的任何其它因素。 因此，本发明提供了用于开发新型治疗剂的有力工具，其中T细胞的活化和扩增可以提供益处。
-
公开(公告)号：US08722400B2
公开(公告)日：2014-05-13
申请号：US12796445
申请日：2010-06-08
IPC分类号： C12N5/07
CPC分类号： A61K39/39 , A61K39/12 , A61K39/21 , A61K47/642 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , A61K2039/55522 , A61K2039/55527 , A61K2039/55533 , C12N5/0634 , C12N5/0635 , C12N5/0636 , C12N5/0694 , C12N15/86 , C12N2501/23 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00 , C12N2740/15043 , G01N33/505 , G01N33/56972
摘要： The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
摘要翻译： 本发明涉及新型人造抗原呈递细胞（aAPCs）。 aAPC包含至少一种刺激性配体和至少一种共刺激配体，其中配体各自特异性结合感兴趣的T细胞上的同源分子，从而介导T细胞的扩增。 本发明的aAPC可进一步包含可用于扩增感兴趣的T细胞的其它分子。 本发明的aAPC可以用作可以容易地设计用于扩大感兴趣的T细胞的“现成”APC。 此外，可以使用本发明的aAPC来鉴定刺激性，共刺激性和介导感兴趣的T细胞的生长和扩增的任何其它因素。 因此，本发明提供了用于开发新型治疗剂的有力工具，其中T细胞的活化和扩增可以提供益处。
-
公开(公告)号：US20110262467A1
公开(公告)日：2011-10-27
申请号：US12796445
申请日：2010-06-08
CPC分类号： A61K39/39 , A61K39/12 , A61K39/21 , A61K47/642 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , A61K2039/55522 , A61K2039/55527 , A61K2039/55533 , C12N5/0634 , C12N5/0635 , C12N5/0636 , C12N5/0694 , C12N15/86 , C12N2501/23 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00 , C12N2740/15043 , G01N33/505 , G01N33/56972
摘要： The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
摘要翻译： 本发明涉及新型人造抗原呈递细胞（aAPCs）。 aAPC包含至少一种刺激性配体和至少一种共刺激配体，其中配体各自特异性结合感兴趣的T细胞上的同源分子，从而介导T细胞的扩增。 本发明的aAPC可进一步包含可用于扩增感兴趣的T细胞的其它分子。 本发明的aAPC可以用作可以容易地设计用于扩大感兴趣的T细胞的“现成”APC。 此外，可以使用本发明的aAPC来鉴定刺激性，共刺激性和介导感兴趣的T细胞的生长和扩增的任何其它因素。 因此，本发明提供了用于开发新型治疗剂的有力工具，其中T细胞的活化和扩增可以提供益处。
-
公开(公告)号：US07385023B1
公开(公告)日：2008-06-10
申请号：US10130413
申请日：2000-11-15
申请人： Joachim L. Schultze , Robert H. Vonderheide , David Sherr , Lee M. Nadler , Britta Maecker , Michael Bergwelt-Baildon
发明人： Joachim L. Schultze , Robert H. Vonderheide , David Sherr , Lee M. Nadler , Britta Maecker , Michael Bergwelt-Baildon
IPC分类号： A61K38/00
摘要： The invention provides methods for conducting cancer immunotherapy and diagnosis using cytochrome P450 1B1 and peptide fragments thereof.
摘要翻译： 本发明提供使用细胞色素P450 1B1及其肽片段进行癌症免疫治疗和诊断的方法。
-
公开(公告)号：US5599676A
公开(公告)日：1997-02-04
申请号：US323199
申请日：1994-10-14
IPC分类号： A61K38/00 , C07K14/705 , C07K16/28 , C12N1/21 , G01N33/569 , G01N33/68 , C12Q1/02 , C07K16/00 , C12N15/12
CPC分类号： G01N33/6887 , C07K14/7055 , C07K16/2842 , G01N33/56972 , A61K38/00
摘要： The present invention is directed to a method for isolating a novel receptor for .alpha.4 integrins such as VLA-4, that is distinct from VCAM-1 and from fibronectin. Isolated nucleic acids encoding the receptor and antibodies to the receptor are also provided. The invention is also directed to pharmaceutical compositions, and methods of treating disorders involving an undesirable inflammatory or immune response by administering the VLA-4 receptor of the invention.
摘要翻译： 本发明涉及用于分离α4整联蛋白的新受体的方法，所述α4整联蛋白例如不同于VCAM-1和来自纤连蛋白的VLA-4。 还提供了编码受体的分离的核酸和对受体的抗体。 本发明还涉及通过施用本发明的VLA-4受体来治疗涉及不期望的炎症或免疫应答的病症的药物组合物和方法。
-
6.发明授权Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT 有权癌症免疫治疗和诊断使用通用肿瘤相关抗原，包括hTERT公开(公告)号：US07851591B1
公开(公告)日：2010-12-14
申请号：US09830400
申请日：1999-10-29
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C12N5/0639
摘要： The invention provides methods for conducting cancer immunotherapy and diagnosis using universal tumor associated antigens, such as the telomerase catalytic subunit (hTERT), and methods for identifying and characterizing universal tumor associated antigens.
摘要翻译： 本发明提供使用通用肿瘤相关抗原如端粒酶催化亚单位（hTERT）进行癌症免疫治疗和诊断的方法，以及用于鉴定和表征普遍肿瘤相关抗原的方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.04 秒)
